CAS: 134404-52-7; (1R,3S,Z)-5-((E)-2-((1R,3As,7Ar)-1-((R,3E,5E)-7-Ethyl-7-Hydroxynona-3,5-Dien-2-yl)-7A-Methylhexahydro-1H-Inden-4(2H)-Ylidene)Ethylidene)-4-Methylenecyclohexane-1,3-Diol

该化合物是维生素D3的合成衍生物,主要用于治疗某些皮肤病,特别是皮质丝虫病,具有与天然维生素D相似的特性,包括能够调节体内的钙和磷酸盐代谢;Seocalcitool功能与维生素D受体结合,影响基因表达,促进细胞分化和扩散;其治疗效果可归因于其调节免疫反应和抑制皮肤细胞扩散的能力,使其在皮肤学应用中有益;该化合物通常以专题方式进行施用,其功效经常在临床环境中进行评估;与其他维生素D类物一样,潜在的副作用可能包括高血糖和皮肤刺激,需要在治疗期间进行仔细监测;

结构式图片

相似化合物

66791-71-7 73837-24-8 32222-06-3

欧盟法规

C&L通报

合成工艺路线路线简述

    8-[4-[2-[3,5-Bis[[tert-Butyl(Dimethyl)Silyl]Oxy]-2-Methylidenecyclohexylidene]Ethylidene]-7A-Methyl-2,3,3A,5,6,7-Hexahydro-1H-Inden-1-Yl]-3-Ethylnona-4,6-Dien-3-Ol 反应生成西奥骨化醇
    参考文献:Org. Process Res. Dev. 2004,8,133-135
    标题:Org. Process Res. Dev. 2004,8,133-135

    海关参考信息

    专利信息


    专利号:US-2017283878-A1
    优先权日:2015-12-11
    标题:Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
    发明人:WONG CHI-HUEY; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI; HSU TSUI-LING
    权利人:ACADEMIA SINICA
    摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for diagnostic and therapeutic uses.

    专利号:US-9221753-B2
    优先权日:2004-02-03
    标题:Process for the synthesis of vitamin D compounds and intermediates for the synthesis of the compounds
    发明人:KASHIWAGI HIROTAKA; ONO YOSHIYUKI
    权利人:KASHIWAGI HIROTAKA; ONO YOSHIYUKI; CHUGAI PHARMACEUTICAL CO LTD
    摘要:An object of the present invention is to provide a process for synthesizing a vitamin D compound by simple procedures at lower costs. n The present invention provides a process for preparing a vitamin D compound and an intermediate thereof, comprising the step of: (a) mixing a ketone or aldehyde, a Wittig reagent, and a base; or (b) mixing a ketone or aldehyde and a Wittig reagent, and then adding a base to the resulting mixture.

    专利号:US-2007135394-A1
    优先权日:2004-02-03
    标题 :Process for the synthesis of vitamin d compounds and intermediates for the synthesis of the compounds

    专利号:US-10272065-B2
    优先权日:2013-01-14
    标题 :Gem-difluorinated C-glycoside compounds as anti-cancer agents
    发明人:SLILATY STEVE N
    权利人:ADVANOMICS CORP; BENOIT & COTE
    摘要:The present document describes a synthesis of a class of gem-difluorinated C-glycoside compounds derived from podophyllotoxin, which may be used, but not exclusively, in oncology for the treatment of cancer. More particularly, the podophyllotoxin gem-difluorinated C-glycoconjugated derivatives display improved conformational and chemical stability, and improved cytotoxicity exhibited against drug-resistant cancer cell lines.
    甘肃皓天科技股份有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.haotianpharmatech.com/
    电话: 0943-6900332 17789447501👤
    📞甘肃皓天科技股份有限公司 ⚠️参考联系方式

    销售电话:0943-6900332 17789447501
    邮箱:zhuanxiajiang@haotianpharm.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    摘要:S109 | PARCEDC | List of 7074 potential endocrine disrupting compounds (EDCs) by PARC T4.2 | DOI:10.5281/zenodo.10944198
    摘要:El Abdaimi K, Papavasiliou V, Rabbani SA, Rhim JS, Goltzman D, Kremer R. Reversal of hypercalcemia with the vitamin D analogue EB1089 in a human model of squamous cancer. Cancer Res. 1999 Jul 15;59(14):3325–8.
    参考文献:10.1210/en.136.1.20|10.1210/endo.136.1.7530193
    摘要:Skowronski RJ, Peehl DM, Feldman D. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology. 1995 Jan;136(1):20–6. doi: 10.1210/endo.136.1.7530193.
    参考文献:10.1038/nm1095
    摘要:Pálmer HG, Larriba MJ, García JM, Ordóñez-Morán P, Peña C, Peiró S, Puig I, Rodríguez R, de la Fuente R, Bernad A, Pollán M, Bonilla F, Gamallo C, de Herreros AG, Muñoz A. The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer. Nat Med. 2004 Sep;10(9):917–9. doi: 10.1038/nm1095.
    参考文献:10.1210/en.2009-0991
    摘要:Washington MN, Weigel NL. 1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion. Endocrinology. 2010 Apr;151(4):1409–17.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知